key: cord-0719148-vxyd9k3x
authors: Tang, J.
title: What can we learn about corticosteroid therapy as a treatment for COVID-19?
date: 2020-06-09
journal: Osteoporos Int
DOI: 10.1007/s00198-020-05487-w
sha: f9ff2d07eea8f230353212483c9d3fcd45aa05f8
doc_id: 719148
cord_uid: vxyd9k3x

nan

question the patient to determine if there is any discomfort, such as joint pain, and use magnetic resonance imaging (MRI) to detect osteonecrosis, especially necrosis of the femoral head, if necessary. Second, the patient's blood calcium, phosphine, 25-hydroxyvitamin D, parathyroid hormone (PTH), and bone density should be monitored. Third, adequate dietary intake of calcium (1000 mg per day) and vitamin D (600 to 800 IU) and other appropriate treatments according to the patient's condition are routinely encouraged to prevent osteoporosis in patients beginning corticosteroid treatment [4] .

Competing interests No relevant disclosures.

Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the

Glucocorticoid-induced osteoporosis

Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations